3653 results for «439»

Filter By

3653 results

Coronary interventions: first-in-man and novel devices

20 May 2026 – From EuroPCR 2026

Explore pioneering advancements in coronary interventions with first-in-man and novel devices. This session presents groundbreaking studies including cryotherapy for vulnerable plaques, a novel intravascular crossing system for coronary CTOs, sirolimus-coated retrievable scaffold therapy for in-stent restenosis, real-time intravascular photoacoustic imaging of lipid-rich plaques, and the inaugural...

Bifurcation PCI with complications - Part 2

20 May 2026 – From EuroPCR 2026

This session addresses the challenges and complications encountered during bifurcation PCI. Topics include managing the hairpin hazard, advanced techniques for coronary guidewire entrapment, dual device failure in complex interventions, strategies for trifurcation lesions, and the implications of tissue entrapment in malapposed stents within the left main...

When the anterior leaflet gets in the way: mitral leaflet modification before TMVR

19 May 2026 – From EuroPCR 2026

This session addresses the intricacies of mitral leaflet modification techniques prior to transcatheter mitral valve replacement (TMVR). It features innovative approaches such as LAMPOON-assisted valve-in-ring replacement, balloon-assisted leaflet translocation, and strategies to overcome the challenges posed by mitral annular calcification.

PCR's Got Talent Round 1 - Session 2

19 May 2026 – From EuroPCR 2026

PCR's Got Talent Round 1 - Session 2 offers a diverse collection of studies addressing coronary microvascular dysfunction, atrial fibrillation management, TAVI outcomes, AI applications in imaging, mitral and tricuspid valve interventions, and in-stent restenosis treatment. The session culminates with deliberations and results announcements, reflecting cutting-edge...

How to face resistent hypertension: when pharmacological treatment is not an option

19 May 2026 – From EuroPCR 2026

Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.

FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case

19 May 2026 – From EuroPCR 2026

A 71‑year‑old man with hypertension and dyslipidemia presented with CCS class II angina and three‑vessel coronary artery disease. Functional assessment included CT‑derived micro‑FFR, angiography‑based FFR, and stress myocardial scintigraphy. The only hemodynamically significant lesion was a long, calcified lesion of the LAD.

Lesion preparation was performed with...

FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case

TAVI procedural complications - Part 3: vascular complications, coronary issues and more

19 May 2026 – From EuroPCR 2026

This session addresses critical procedural complications during TAVI, emphasizing vascular issues, coronary complications, and complex bailout scenarios. Through challenging case examples, it offers insights into the management and anticipation of such complications to optimize patient outcomes.

Identifying problems and solving complex anatomies during TAVI

19 May 2026 – From EuroPCR 2026

A comprehensive session on managing complex anatomies during Transcatheter Aortic Valve Implantation (TAVI), emphasizing risk markers for peri-operative complications and strategies to address difficult anatomical challenges. Real-world cases illustrate practical approaches and key learnings for handling intricate TAVI scenarios.

EuroPCR 2026 – Coronary revascularisation in patients undergoing TAVI

20 May 2026

Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is an individual participant data meta-analysis of 4 randomised controlled trials...

EuroPCR 2026 – Coronary revascularisation in patients undergoing TAVI

BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

07 Nov 2022

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Nicola Ryan

Author

Nicola Ryan
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

Three-year results of HOST-POLYTECH-ACS RCT comparing durable- vs. degradable-polymer DES

30 Aug 2023

Alex Sticchi provides his take on the 3-year results of HOST-POLYTECH-ACS RCT which were presented by Hyo-Soo Kim during the ESC 2023 congress in Amsterdam.

Alessandro Sticchi

Author

Alessandro Sticchi
Three-year results of HOST-POLYTECH-ACS RCT comparing durable- vs. degradable-polymer DES

Evidence base: A description of the key, so far published, studies in the space of drug coated balloons

23 Jan 2025

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Author

Hector Garcia-Garcia
Jorge Sanz Sanchez

Author

Jorge Sanz-Sanchez
Evidence base: A description of the key, so far published, studies in the space of drug coated balloons

NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome

02 Sep 2025

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Daniele Giacoppo

Author

Daniele Giacoppo
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
Didn’t find what you were looking for?